Trial reportDiabetes care2011
Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk.
Trial report in Diabetes care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 175 citations in OpenAlex.
- Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.Health technology assessment (Winchester, England) · 2024Pooled it
- Trial
- Hypoglycemia Reduction and Changes in Hemoglobin A1c in the ASPIRE In-Home Study.Diabetes technology & therapeutics · 2015Trial
- Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.The lancet. Diabetes & endocrinology · 2014Trial
- Safety of nighttime 2-hour suspension of Basal insulin in pump-treated type 1 diabetes even in the absence of low glucose.Diabetes care · 2014Trial
- Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system.Diabetes care · 2014Trial
- Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia.Diabetes technology & therapeutics · 2013Trial
- ASPIRE In-Home: rationale, design, and methods of a study to evaluate the safety and efficacy of automatic insulin suspension for nocturnal hypoglycemia.Journal of diabetes science and technology · 2013Trial
- Inpatient studies of a Kalman-filter-based predictive pump shutoff algorithm.Journal of diabetes science and technology · 2012Trial
- Analysis of glucose responses to automated insulin suspension with sensor-augmented pump therapy.Diabetes care · 2012Trial
- New Technologies for Blood Glucose Management in Elderly Diabetics: An Interpretation of theAging medicine (Milton (N.S.W)) · 2025Review
- The Evolution of Insulin Administration in Type 1 Diabetes.Journal of diabetes mellitus · 2021Article
- Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?Biomolecules · 2021Review
- Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives.Reviews in endocrine & metabolic disorders · 2021Review
- Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon.Diabetes, obesity & metabolism · 2020Review
- Prediction of Nocturnal Hypoglycemia in Adults with Type 1 Diabetes under Multiple Daily Injections Using Continuous Glucose Monitoring and Physical Activity Monitor.Sensors (Basel, Switzerland) · 2020Article
- Severe Hypoglycemia: Is It Still a Threat for Children and Adolescents With Type 1 Diabetes?Frontiers in endocrinology · 2020Review
- Combining continuous glucose monitoring and insulin pumps to automatically tune the basal insulin infusion in diabetes therapy: a review.Biomedical engineering online · 2019Review
- Continuous Subcutaneous Insulin Infusion Characteristics in Type 1 Diabetes Children and Adolescents in Qatar.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Article
- Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology.Current diabetes reports · 2018Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo evaluate a sensor-augmented insulin pump with a low glucose suspend (LGS) feature that automatically suspends basal insulin delivery for up to 2 h in response to sensor-detected hypoglycemia. RESEARCH DESIGN AND
methodsThe LGS feature of the Paradigm Veo insulin pump (Medtronic, Inc., Northridge, CA) was tested for 3 weeks in 31 adults with type 1 diabetes.
resultsThere were 166 episodes of LGS: 66% of daytime LGS episodes were terminated within 10 min, and 20 episodes lasted the maximum 2 h. LGS use was associated with reduced nocturnal duration ≤2.2 mmol/L in those in the highest quartile of nocturnal hypoglycemia at baseline (median 46.2 vs. 1.8 min/day, P = 0.02 [LGS-OFF vs. LGS-ON]). Median sensor glucose was 3.9 mmol/L after 2-h LGS and 8.2 mmol/L at 2 h after basal restart.
conclusionsUse of an insulin pump with LGS was associated with reduced nocturnal hypoglycemia in those at greatest risk and was well accepted by patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.